United states securities and exchange commission

Table of Contents
F- 6
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY
(In millions)
 
Preferred stock
Common stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Retained
earnings
Treasury stock
Total
Biogen Inc.
shareholders’
equity
Noncontrolling
interests
Total
equity
 
Shares
Amount
Shares
Amount
Shares
Amount
Balance, December 31,
2016
— $ —
238.5 $ 0.1 $
— $
(319.9) $15,071.6
(22.6) $(2,611.7) $ 12,140.1 $
(11.5) $12,128.6
Net income
2,539.1
2,539.1
131.0
2,670.1
Other comprehensive
income (loss), net of tax
1.5
1.5
—
1.5
Capital contribution by
noncontrolling interest
—
15.8
15.8
Distribution to
noncontrolling interest
—
(150.0)
(150.0)
Repurchase of common
stock pursuant to the
2016 Share Repurchase
Program, at cost
(3.7)
(1,000.0)
(1,000.0)
(1,000.0)
Retirement of common
stock pursuant to the
2016 Share Repurchase
Program, at cost
(3.7)
—
(36.0)
(964.0)
3.7
1,000.0
—
—
Repurchase of common
stock pursuant to the
2011 Share Repurchase
Program, at cost
(1.2)
(365.4)
(365.4)
(365.4)
Issuance of common
stock under stock option
and stock purchase
plans
0.2
—
40.5
—
40.5
40.5
Issuance of common
stock under stock award
plan
0.3
—
(44.8)
(1.0)
(45.8)
(45.8)
Compensation related to
share-based payments
138.1
138.1
138.1
Hemophilia spin-off
adjustment
(852.8)
(852.8)
(852.8)
Tax benefit
17.5
17.5
17.5
Balance, December 31,
2017
— $ —
235.3 $ 0.1 $
97.8 $
(318.4) $15,810.4
(23.8) $(2,977.1) $ 12,612.8 $
(14.7) $12,598.1
See accompanying notes to these consolidated financial statements.

---

Table of Contents
F- 7
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY - (Continued)
(In millions)
 
Preferred stock
Common stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Retained
earnings
Treasury stock
Total
Biogen Inc.
shareholders’
equity
Noncontrolling
interests
Total
equity
Shares
Amount
Shares
Amount
Shares
Amount
Balance, December 31,
2015
— $
—
241.2 $ 0.1 $
— $
(224.0) $12,208.4
(22.6) $(2,611.7) $ 9,372.8 $
2.1 $ 9,374.9
Net income
3,702.8
3,702.8
(7.1)
3,695.7
Other comprehensive
income (loss), net of tax
(95.9)
(95.9)
0.1
(95.8)
Acquisition of
noncontrolling interest
—
(0.6)
(0.6)
Capital contribution by
noncontrolling interest
—
1.5
1.5
Deconsolidation of
noncontrolling interest
—
(7.5)
(7.5)
Repurchase of common
stock pursuant to the
2016 Share Repurchase
Program, at cost
(3.3)
(1,000.0)
(1,000.0)
(1,000.0)
Retirement of common
stock pursuant to the
2016 Share Repurchase
Program, at cost
(3.3)
—
(164.9)
(835.1)
3.3
1,000.0
—
—
Issuance of common
stock under stock option
and stock purchase
plans
0.2
—
43.7
43.7
43.7
Issuance of common
stock under stock award
plan
0.4
—
(47.6)
(4.5)
(52.1)
(52.1)
Compensation related to
share-based payments
169.4
169.4
169.4
Tax benefit from share-
based payments
(0.6)
(0.6)
(0.6)
Balance, December 31,
2016
— $
—
238.5 $ 0.1 $
— $
(319.9) $15,071.6
(22.6) $(2,611.7) $ 12,140.1 $
(11.5) $12,128.6
See accompanying notes to these consolidated financial statements.

---

Table of Contents
F- 8
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EQUITY - (Continued)
(In millions)
Preferred stock
Common stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Retained
earnings
Treasury stock
Total
Biogen Inc.
shareholders’
equity
Noncontrolling
interests
Total
equity
Shares
Amount
Shares
Amount
Shares
Amount
Balance, December 31,
2014
— $
—
257.1 $ 0.1 $4,196.2 $
(59.5) $ 9,283.9
(22.6) $(2,611.7) $ 10,809.0 $
5.0 $10,814.0
Net income
3,547.0
3,547.0
46.2
3,593.2
Other comprehensive
income (loss), net of tax
(164.5)
(164.5)
—
(164.5)
Distribution to
noncontrolling interests
—
(60.0)
(60.0)
Acquisition of
noncontrolling interests
—
10.9
10.9
Repurchase of common
stock pursuant to the
2015 Share Repurchase
Program, at cost
(16.8)
(5,000.0)
(5,000.0)
(5,000.0)
Retirement of common
stock pursuant to the
2015 Share Repurchase
Program, at cost
(16.8)
—
(4,377.5)
(622.5)
16.8
5,000.0
—
—
Issuance of common
stock under stock option
and stock purchase
plans
0.3
—
54.2
54.2
54.2
Issuance of common
stock under stock award
plan
0.6
—
(125.1)
(125.1)
(125.1)
Compensation related to
share-based payments
183.2
183.2
183.2
Tax benefit from share-
based payments
69.0
69.0
69.0
Balance, December 31,
2015
— $
—
241.2 $ 0.1 $
— $
(224.0) $12,208.4
(22.6) $(2,611.7) $ 9,372.8 $
2.1 $ 9,374.9
See accompanying notes to these consolidated financial statements.

---